Publication | Closed Access

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

Hematological MalignancyLymphoid NeoplasiaMedicineReduced-dose ChopImmunotherapyOncologyRadiation OncologyLysa Group